Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Tissue Plasminogen Activator Clear all

Conditions: Stroke
Interventions: 2-MHz transcranial Doppler ultrasound, 2-MHz transcranial Doppler ultrasound insonation; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Birmingham, Alabama • Houston, Texas

Conditions: Menstrual Bleeding, Heavy
Interventions: Sample Collection and Endometrial Biopsy; Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Stroke
Interventions: Alteplase; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ischemic Stroke
Interventions: Computed tomography perfusion imaging; Other
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Empyema
Interventions: tPA alone, tPA plus dornase; Biological
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: Up to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions: Recombinant tissue plasminogen activator (rt-PA); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 16 Years to 75 Years
Enrollment: 692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 56
States / cities: Glendale, Arizona • Orange, California • Stanford, California + 48 more

Conditions: Acute Ischemic Stroke
Interventions: Thrombectomy; Procedure
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 90 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Ischemic Stroke
Interventions: Tenecteplase, Alteplase; Drug
Lead sponsor: Reza Behrouz, DO; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Stroke
Interventions: hypothermia, tissue plasminogen activator; Procedure · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 7
States / cities: Palo Alto, California • San Diego, California • Hartford, Connecticut + 2 more

Conditions: Acute Submassive Pulmonary Embolism
Interventions: The Bashir™ Endovascular Catheter (BEC; Device
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ischemic Stroke
Interventions: Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase); Drug
Lead sponsor: Andrew D. Barreto, MD; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Limb Ischemia
Interventions: MST-188, Saline; Drug
Lead sponsor: Mast Therapeutics, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 4
States / cities: Little Rock, Arkansas • Tampa, Florida • Brooklyn, New York + 1 more

Conditions: Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder, Pleural Effusions
Interventions: Pleural Saline Irrigation; Combination Product
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Transplantation
Interventions: Bradykinin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Tissue Plasminogen Activator
Interventions: early tPA and DNase; Combination Product
Lead sponsor: Prisma Health-Midlands; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Cerebral Hemorrhage
Interventions: Recombinant Tissue Plasminogen Activator (rt-PA); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ischemic Stroke, Atrial Fibrillation, Transient Ischemic Attacks, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke of Basilar Artery, Cardioembolic Stroke
Interventions: Biomarker blood draw; Other
Lead sponsor: Ischemia Care LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 22
States / cities: Sacramento, California • San Francisco, California • Detroit, Michigan + 17 more

Conditions: Acute Deep Venous Thrombosis of the Lower Extremity
Interventions: Alteplase (Activase, Genentech); Drug
Lead sponsor: Richard Chang, M.D.; NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity
Interventions: Bradykinin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Stroke
Interventions: Barrier assessment / interactive educational intervention; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Ischemic Stroke
Interventions: YM872 (zonampanel), t-PA (alteplase); Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 94
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more

Conditions: Stroke
Interventions: activase, integrilin; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 80 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 19
States / cities: Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 10 more

Conditions: Empyema, Pleural Effusion
Interventions: Alteplase; Drug
Lead sponsor: O'Brien, Jeana D., MD, FACP, FCCP; Individual
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Ischemic Stroke
Interventions: Transcranial Laser Therapy; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Englewood, Colorado • Columbia, South Carolina • Spokane, Washington

Search by objective public record fields.

CLOTBUST Hands-Free: A Phase I/II Pilot Safety Trial

PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis

Quality of Life After Stroke Using a Telemedicine-based Stroke Network

The PERFusion Use in Stroke Evaluation Study

Empyema Treated With tPA & DNAse

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Endovascular Stroke Treatment Only (ESTO) Trial

Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)

Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke

The RESCUE II Study. The Bashir™ Endovascular Catheter (BEC),

Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke

Evaluation of MST-188 in Acute Lower Limb Ischemia

Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients

Early Intrapleural TPA Instillation Versus Late

Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage

Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins

Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation

Increasing Stroke Treatment Through Interventional Change Tactics Study

A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)

Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial

Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion

Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery